Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 2/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 12/20 | 0.55 |
| ▸ | SMO | Q99835 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | RAF1 | P04049 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | TEK | Q02763 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2888962 | 0.81 | MAPK14 (0.59) | BRAFMAPK14SMOKDM4EMAPT | |
| SCHEMBL2888954 | 0.74 | NPC1 (0.52) | BRAFMAPK14SMOKDM4EMAPT | |
| SCHEMBL1265038 | 0.73 | TEK (0.77) | BRAFMAPK14CSF1RBTKTEK | |
| SCHEMBL2891790 | 0.73 | MAPK14 (0.70) | BRAFMAPK14SMOKDM4EMAPT | |
| SCHEMBL2887294 | 0.72 | MAPK14 (0.69) | BRAFMAPK14SMOKDM4EMAPT | |
| SCHEMBL5897054 | 0.72 | MAPK14 (0.65) | BRAFMAPK14SMOKDM4EMAPT | |
| SCHEMBL1264945 | 0.71 | TEK (0.75) | BRAFMAPK14TEK | |
| SCHEMBL3934184 | 0.71 | BRAF (1.00) | BRAFMAPK14CSF1RBTKTEK | |
| SCHEMBL25069020 | 0.70 | MAPK14 (0.63) | BRAFMAPK14SMOKDM4EMAPT | |
| SCHEMBL5007830 | 0.70 | MAPK14 (0.72) | BRAFMAPK14SMOKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197688-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | MSD K.K. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197688-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | MSD K.K. (JP) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197688-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | EPHA4, EPHA1, ERBB4 | BRAF 65/4885MAPK14 146/4885SMO 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.